Biotech Firm Capricor Faces Investor Lawsuits After Hiding Critical Drug Trial Changes

2026-08-04 companies

New York, Monday, 3 August 2026.
Capricor Therapeutics faces securities fraud lawsuits for modifying trial analysis plans for its lead drug without FDA agreement, risking regulatory approval and misleading investors about approval prospects.

Multiple Law Firms File Securities Fraud Claims

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is facing multiple securities class action lawsuits filed by prominent law firms including Bronstein, Gewirtz & Grossman, LLC, Robbins LLP, and the DJS Law Group [1][2][6]. The litigation alleges that the biotech company and its officers made misleading statements regarding business operations and financial health, specifically concerning the regulatory path for its lead product candidate [1][8]. Investors who acquired Capricor securities during the defined Class Period are being urged to contact legal counsel regarding their rights and potential recovery options [7][8]. The consolidated legal action seeks to restore investor capital and ensure corporate accountability following disclosures that negatively impacted shareholder value [1][2].

Allegations Regarding FDA Regulatory Process

The core of the complaint centers on Deramiocel, a cell therapy intended for Duchenne muscular dystrophy, and the company’s interaction with the U.S. Food and Drug Administration (FDA) [2][4]. Lawsuits allege Capricor modified the pre-specified statistical analysis plan (SAP) used for Phase 3 HOPE-3 trial data without securing FDA agreement prior to resubmitting the Biologics License Application (BLA) [2][8]. FDA briefing documents released on July 27, 2026, reportedly confirmed that the final SAP version was not submitted for review or agreed upon by the agency before the BLA submission [4][6]. This lack of alignment created a significant risk that the FDA would conclude the clinical results did not provide substantial evidence of effectiveness, a risk allegedly not disclosed to investors [2][8].

Class Period and Lead Plaintiff Deadlines

The defined Class Period for the securities litigation spans from December 17, 2025, to July 26, 2026, covering the timeframe when alleged misrepresentations were active [1][5]. Investors within this window, which encompasses 222 days, are eligible to seek appointment as lead plaintiff [1][5]. Most law firms, including Bronstein, Gewirtz & Grossman, LLC and the DJS Law Group, have set the deadline for lead plaintiff motions at September 28, 2026 [1][6]. However, some legal representations note a deadline of September 29, 2026, indicating a potential variance in court scheduling or filing requirements that investors should verify [5]. The Private Securities Litigation Reform Act of 1995 mandates a stay on discovery during the pendency of any motion to dismiss to protect defendants from significant expenses [5].

Market Reaction and Stock Performance

Following the disclosure of regulatory hurdles and the subsequent FDA briefing documents, Capricor Therapeutics stock experienced notable volatility [3]. On July 30, 2026, shares traded at $4.19 per share on unusually heavy trading volume, reflecting investor reaction to the unfolding news regarding the BLA resubmission risks [3]. The legal filings suggest that the market was misled regarding the path to FDA approval, and the subsequent reveal of the undisclosed SAP changes contributed to the financial harm suffered by shareholders [2][6]. Legal representation emphasizes that appointment as lead plaintiff is not required to partake in any potential recovery, allowing broader investor participation in the settlement process [6].

Sources

Securities Fraud Capricor Therapeutics